TYPE: New Zealand Research Study
STATUS: In recruitment
GCF CONTRIBUTION: $23,741

GCF has funded Dr Amanda Ashley and her team at Auckland Hospital, for three patients to go onto this valuable trial to the value of $23,741.

ACTICCA-1 is a randomised, controlled, two stage, multicentre Phase III research trial comparing gemcitabine+ cisplatin with standard of care (capecitabine) after curative-intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma.

Cholangiocarcinoma is diagnosed in approximately 80 people every year in New Zealand. In half of these people, curative-intent treatment with surgery is possible. Following this surgery, however, only 20-30% of people survive 5 years. This long-term survival can be increase by giving chemotherapy after the surgery and the current standard is capecitabine. In this research trial, patients received either cisplatin and gemcitabine or capecitabine alone following their surgery. The aim is to find out if giving cisplatin and gemcitabine can improve the outcomes for these patients.